Showing results (51-60 of 77) with videos related to
Sort By:
Pageof 8
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 31, 2011
Inter-individual and inter-cell type variation in residual DNA damage after in vivo irradiation of human skinMelvin Lee Kiang Chua, Navita Somaiah, Sara Bourne, et al.Breast Cancer Research and Treatment|March 29, 2013
Phosphorylation of AKT pathway proteins is not predictive of benefit of taxane therapy in early breast cancerJohn M S Bartlett, Roger A'hern, Tammy Piper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatmentViviane Hess, Roger A'Hern, Nazar Nasiri, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancerMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.Breast Cancer Research : BCR|October 19, 2012
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivoLesley-Ann Martin, Sunil Pancholi, Ian Farmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.Journal of the National Cancer Institute|September 25, 2008
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristicsMatthew J Ellis, Yu Tao, Jingqin Luo, et al.Journal of the National Cancer Institute. Monographs|November 2, 2011
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancerMitch Dowsett, Ian Smith, John Robertson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 2, 2007
Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapyJohn M S Bartlett, Ian O Ellis, Mitch Dowsett, et al.European Journal of Cancer (Oxford, England : 1990)|February 24, 2009
Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a Children's Cancer and Leukaemia Group (CCLG) StudyBoo Messahel, Richard Williams, Antonia Ridolfi, et al.Pageof 8